These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31401877)

  • 61. Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia.
    Frusca T; Gervasi MT; Paolini D; Dionisi M; Ferre F; Cetin I
    J Matern Fetal Neonatal Med; 2017 Sep; 30(18):2166-2173. PubMed ID: 27737599
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
    Frampton GK; Jones J; Rose M; Payne L
    Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The predictive value of the sFlt-1/PlGF ratio in suspected preeclampsia in a New Zealand population: A prospective cohort study.
    Hughes RCE; Phillips I; Florkowski CM; Gullam J
    Aust N Z J Obstet Gynaecol; 2023 Feb; 63(1):34-41. PubMed ID: 35670085
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia.
    Cui L; Shu C; Liu Z; Tong W; Cui M; Wei C; Tang JJ; Liu X; Hu J; Jiang J; He J; Zhang DY; Ye F; Li Y
    Pregnancy Hypertens; 2018 Jul; 13():127-132. PubMed ID: 30177039
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
    Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
    [TBL] [Abstract][Full Text] [Related]  

  • 68. sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective.
    Hodel M; Blank PR; Marty P; Lapaire O
    Dis Markers; 2019; 2019():4096847. PubMed ID: 31485276
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia.
    Tang P; Xu J; Xie BJ; Wang QM
    Hypertens Pregnancy; 2017 Feb; 36(1):48-52. PubMed ID: 27834501
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical usefulness of serum levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio to rule out preeclampsia in women with new-onset lupus nephritis during pregnancy.
    Hirashima C; Ogoyama M; Abe M; Shiraishi S; Sugase T; Niki T; Matsubara S; Ohkuchi A
    CEN Case Rep; 2019 May; 8(2):95-100. PubMed ID: 30565047
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Angiogenic factors can be used when pre-eclampsia is suspected].
    Andrea MK; Lykke JA
    Ugeskr Laeger; 2015 May; 177(22):V11140638. PubMed ID: 26027672
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction.
    Shinohara S; Uchida Y; Kasai M; Sunami R
    Hypertens Pregnancy; 2017 Aug; 36(3):269-275. PubMed ID: 28737473
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia.
    Ohkuchi A; Hirashima C; Suzuki H; Takahashi K; Yoshida M; Matsubara S; Suzuki M
    Hypertens Res; 2010 May; 33(5):422-7. PubMed ID: 20150910
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Urinary sFlt-1 and PlGF levels are strongly correlated to serum sFlt-1/PlGF ratio and serum PlGF in women with preeclampsia.
    Hebert-Schuster M; Ranaweera T; Fraichard C; Gaudet-Chardonnet A; Tsatsaris V; Guibourdenche J; Lecarpentier E
    Pregnancy Hypertens; 2018 Apr; 12():82-83. PubMed ID: 29674205
    [No Abstract]   [Full Text] [Related]  

  • 76. Longitudinal change of sFlt-1/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction.
    Herraiz I; Quezada MS; Rodriguez-Calvo J; Gómez-Montes E; Villalaín C; Galindo A
    Ultrasound Obstet Gynecol; 2018 Nov; 52(5):631-638. PubMed ID: 28876491
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Relationships of serum placental growth factor and soluble fms-like tyrosine kinase-1 with fetal and uterine artery Doppler indices in pre-eclampsia.
    Li J; Cai A; Yuan Q; Ding H; Zhao D
    Int J Gynaecol Obstet; 2019 May; 145(2):176-181. PubMed ID: 30801711
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Predictive and prognostic factors of preeclampsia: Interest of PlGF and sFLT-1].
    Vieillefosse S; Guibourdenche J; Atallah A; Haddad B; Fournier T; Tsatsaris V; Lecarpentier E
    J Gynecol Obstet Biol Reprod (Paris); 2016 Nov; 45(9):999-1008. PubMed ID: 27212611
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Circulating angiogenic factors and the risk of preeclampsia.
    Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preeclampsia and superimposed preeclampsia: The same disease? The role of angiogenic biomarkers.
    Costa RA; Hoshida MS; Alves EA; Zugaib M; Francisco RP
    Hypertens Pregnancy; 2016 May; 35(2):139-49. PubMed ID: 26930132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.